BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37706238)

  • 1. Malignant phyllodes tumour with lymph node metastasis: a diagnostic conundrum resolved by next generation DNA sequencing.
    Schwartz CJ; Krings G; Chen YY
    Histopathology; 2024 Jan; 84(2):409-411. PubMed ID: 37706238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis.
    Korula A; Varghese J; Thomas M; Vyas F; Korula A
    Singapore Med J; 2008 Nov; 49(11):e318-21. PubMed ID: 19037540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MED12 exon 2 mutation as a highly sensitive and specific marker in distinguishing phyllodes tumours from other spindle neoplasms of the breast.
    Lien HC; Huang CS; Yang YW; Jeng YM
    APMIS; 2016 May; 124(5):356-64. PubMed ID: 26860948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
    Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
    J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
    Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma.
    Yeong J; Thike AA; Young Ng CC; Md Nasir ND; Loh K; Teh BT; Tan PH
    Pathology; 2017 Dec; 49(7):786-789. PubMed ID: 29066183
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
    Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
    Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
    Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
    Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Grade Spindle Cell Lesions of the Breast: Key Pathologic and Clinical Updates.
    Yoon E; Ding Q; Hunt K; Sahin A
    Surg Pathol Clin; 2022 Mar; 15(1):77-93. PubMed ID: 35236635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
    Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MED12 exon 2 mutations in phyllodes tumors of the breast.
    Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
    Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
    Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
    J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign phyllodes tumor of the breast recurring as a malignant phyllodes tumor and spindle cell metaplastic carcinoma.
    Muller KE; Tafe LJ; de Abreu FB; Peterson JD; Wells WA; Barth RJ; Marotti JD
    Hum Pathol; 2015 Feb; 46(2):327-33. PubMed ID: 25476122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent
    Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
    J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periductal Stromal Tumor of the Breast with a
    Anderson B; Marotti JD; Lefferts JA; Muller KE
    Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
    Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
    Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: A case report.
    Zhou P; Zhang Q; Zhu J; Li P
    Pathol Res Pract; 2021 Aug; 224():153489. PubMed ID: 34091389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.